Participate in a research study at PRC: Newcastle

Our new modern research facility is easily accessible for patients and parking. Here you will receive a warm welcome from our friendly and professional team. We offer a number of ways to make it easier to take part in a research study, including extended hours, video consultations and virtual trials (where you don’t need to attend in person).

On this page you can find out about studies we are currently delivering, upcoming studies, and studies that we have delivered in the past.

Open studies that are accepting new participants

These studies are currently seeking new participants. Use the links below to access more information about each study.

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

20170703 is a study in adult participants with Chronic Migraine (CM) and Medication Overuse Headache (MOH). The purpose of conducting the study is to better understand the effectiveness and safety of erenumab compared to placebo when given to a targeted population diagnosed with CM and MOH that have at least one preventative treatment failure, to see if it makes any changes in the number of days participants suffer from monthly headache days (MHD) and are able to revert the medication overuse status.

After consenting, participants will enter the screening period (up to 7 weeks), following which eligible participants (approximately 687) will be randomised in a 1:1:1 fashion to either placebo, erenumab 70mg or erenumab 140mg for 24 weeks (double blind treatment phase (DBTP)), the participants then have the option to enter the open-label treatment phase (OLTP) for 28 weeks. Participants on erenumab will continue with the same treatment whereas those participants previously on placebo will be randomised into either erenumab 70mg or erenumab 140mg. At the end of treatment, participants will have an End of Study visit 4 weeks after the last dose.

Participants are expected to complete 12 on site study visits and 4 telephone calls. The planned length of participation for each participant is up to 59 weeks.

Participants will use an electronic diary daily during the DBTP and then part of the OLTP in order to collect information about headaches, medication and complete questionnaires.

Erenumab works by blocking a cell receptor, which is a key factor in causing migraines. Participants that suffer from migraines, frequently take pain medication that overtime can become less effective in treating migraines and lead to a condition known as MOH, by taking erenumab the study is trying to see if it will revert the medication overuse status.

Upcoming studies

These studies are currently being planned. Where possible, we have tried to indicate when the study may open for participants. Check this page frequently for updates.


The CORVIS trial is investigating the use of a new drug (inhaled via a handheld nebuliser to produce nitric oxide in the lungs) for treatment of infective exacerbations of COPD and bronchiectasis. Nitric oxide plays a key part in our body’s own defence against microbial infection in the lungs and has already been approved for use in the treatment of lung disease in neonates. In this study it will be used in addition to the usual treatment you would receive during an infective exacerbation, such as oral steroids and antibiotics.

Closed studies

These studies are no longer seeking new patients. Where possible, we will update the information links below when the study findings are published and with related information.

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

This study is testing a treatment called remdesivir to understand if it can help prevent or reduce hospitalization of people with early stage COVID-19.


Enterosgel® in the treatment of Irritable Bowel Syndrome with diarrhoea (RELIEVE IBS-D study)

The RELIEVE IBS-D trial is testing a new treatment for Irritable Bowel Syndrome with Diarrhoea (IBS-D).


The MANDALA study is investigating a new drug for people who are currently living with moderate to severe asthma.

Related pages